Obesity White Papers & Case Studies

  1. Successful SwissMedic Marketing Authorization Application For An Oncology Therapy 6/4/2026

    See how strategic EU dossier adaptation and Swiss-specific regulatory expertise enabled a successful SwissMedic submission and accelerated market access for an oncology therapy.

  2. End-To-End Clinical, Biometrics, And Regulatory Support In Neurology 6/4/2026

    Discover how an integrated NDA strategy aligned data, vendors, and regulatory execution to achieve an on-time submission and approval without major FDA queries.

  3. Building A Scalable Oncology Engine In A Dynamic Market 6/3/2026

    Learn how a top-10 global pharmaceutical company partnered with Medable to rapidly scale the number of oncology trials it could concurrently conduct.

  4. Meeting The FDA's New Real-World Evidence Standards 5/27/2026

    FDA guidance is reshaping RWE strategy. Sponsors that build interoperable, audit-ready RWD infrastructure now will be best positioned for faster, defensible submissions.

  5. The eCOA Iceberg 5/27/2026

    Understand the true cost of eCOA deployment, beyond software licenses, to reduce protocol risk, avoid operational bottlenecks, and protect study timelines and data quality.

  6. ICH E6(R3) Is Here: How Should You Handle It? 5/27/2026

    Prepare for ICH E6(R3) with integrated oversight, audit-ready data, and streamlined trial operations designed to reduce burden, accelerate timelines, and support compliance.

  7. Navigating The Challenges Of Large, International Phase III Breast Cancer Trials 5/27/2026

    In the competitive landscape of breast cancer research, aligning biomarker testing, regulatory pathways, and regional operations from day one creates a path to faster enrollment and stronger outcomes.

  8. Data Management Without The Coordination Friction 5/27/2026

    Simplify clinical data management with one connected platform and an expert team delivering faster study startup, cleaner data, fixed-fee predictability, and fewer operational delays.

  9. De-Risking The Neurology IND: Lessons From Early FDA Engagement 5/27/2026

    Learn how early FDA alignment can help your neurology program move forward with greater clarity, confidence, and regulatory readiness.

  10. Successful EU MAA Submission Enabled By U.S.–EU Regulatory Collaboration 5/27/2026

    Facing EU MAA complexity? Learn how one oncology sponsor met a fixed EMA deadline through global regulatory coordination, rapid dossier adaptation, and real-time submission execution.